Moberg Pharma, a Swedish pharmaceutical company, has announced the completion of patient enrolment in the ongoing Phase II trial of MOB-015.

A topical formulation of terbinafine, MOB-015 has been developed for the treatment of onychomycosis (nail fungus) and has fungicidal and keratolytic properties to remove dead cells from the skin’s outermost layer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Moberg Pharma CEO Peter Wolpert said; "MOB-015 has the potential to become a valuable addition to our product portfolio and we look forward to the outcome of the study during next year."

The study is designed to confirm the product concept of MOB-015, as well as provide a basis for a Phase III study and out-licensing.

Patients will be treated for twelve months and later observed for a total of fifteen months, as per the normally accepted FDA and EMA endpoints for nail fungus.

The Phase II study is being conducted at Sahlgrenska University Hospital in Gothenburg, Sweden.